4G/5G and A-844G Polymorphisms of Plasminogen Activator Inhibitor-1 Associated with Glioblastoma in Iran - a Case-Control Study

  • Pooyan, Honari (Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University) ;
  • Ahmad, Ebrahimi (Cellular and Molecular Research Center, Research Institute for Endocrine Sciences) ;
  • Azadeh, Rakhshan (Department of Pathology, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences)
  • Published : 2015.10.06


Background: Glioblastoma is a highly aggressive and malignant brain tumor. Risk factors are largely unknown however, although several biomarkers have been identified which may support development, angiogenesis and invasion of tumor cells. One of these biomarkers is PAI-1.4G/5G and A-844G are two common polymorphisms in the gene promotor of PAI 1 that may be related to high transcription and expression of this gene. Studies have shown that the prevalence of the 4G and 844G allele is significantly higher in patients with some cancers and genetic disorders. Materials and Methods: We here assessed the association of 4G/5G and A-844G polymorphisms with glioblastoma cancer risk in Iranians in a case-control study. All 71 patients with clinically confirmed and 140 volunteers with no history and symptoms of glioblastoma as control group were screened for 4G/5G and A-844G polymorphisms of PAI-1, using ARMS-PCR. Genotype and allele frequencies of case and control groups were analyzed using the DeFinetti program. Results: Our results showed significant associations between 4G/5G (p=0.01824) and A-844G (p = 0.02012) polymorphisms of the PAI-1 gene with glioblastoma cancer risk in our Iranian population. Conclusions: The results of this study supporting an association of the PAI-1 4G/5G (p=0.01824) and A-844G (p = 0.02012) polymorphisms with increasing glioblastoma cancer risk in Iranian patients.


Biological markers;glioblastoma;plasminogen activator inhibitor 1;polymorphisms;risk factors


  1. Andreasen PA (2007). PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets, 8, 1030-41.
  2. Bajou K, Masson V, Gerard RD, et al (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol, 152, 777-84.
  3. Berger DH (2002). Plasmin/plasminogen system in colorectal cancer. World J Surg, 26, 767-71.
  4. Binder BR, Christ G, Gruber F, et al (2002). Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci, 17, 56-61.
  5. Bleeker FE, Molenaar RJ, Leenstra S (2012). Recent advances in the molecular understanding of glioblastoma. J Neurooncol, 108, 11-27.
  6. Brandal S, Blake CM, Sullenger BA, et al (2011). Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Ther, 21, 373-81.
  7. Czekay RP, Wilkins-Port CE, Higgins SP, et al (2011). PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol, 2011, 562481.
  8. Dano K, Behrendt N, Hoyer-Hansen G, et al (2005). Plasminogen activation and cancer. Thromb Haemost, 93, 676-81.
  9. Das BR, Tangri R, Ahmad F, et al (2013). Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. Asian Pac J Cancer Prev, 14, 7261-4.
  10. Eriksson P, Kallin B, van 't Hooft FM, et al (1995). Allelespecific increase in basal transcription of the plasminogenactivator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A, 92, 1851-5.
  11. Gomes-Giacoia E, Miyake M, Goodison S, et al (2013). Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther, 12, 2697-708.
  12. Grubic N, Stegnar M, Peternel P, et al (1996). A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res, 84, 431-43.
  13. Halamkova J, Kiss I, Pavlovsky Z, et al (2013). Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. Neoplasma, 60, 151-9.
  14. Isogai C, Laug WE, Shimada H, et al (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res, 61, 5587-94.
  15. Jiang Y, Uhrbom L (2012). On the origin of glioma. Ups J Med Sci, 117, 113-21.
  16. McNamara MG, Sahebjam S, Mason WP (2013). Emerging biomarkers in glioblastoma. Cancers (Basel), 5, 1103-19.
  17. Ren F, Shi H, Zhang G, et al (2013). Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. J Exp Clin Cancer Res, 32, 60.
  18. Serao NV, Delfino KR, Southey BR, et al (2011). Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics, 4, 49.
  19. Serce NB, Boesl A, Klaman I, et al (2012). Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. BMC Cancer, 12, 597.
  20. Sreekanthreddy P, Srinivasan H, Kumar DM, et al (2010). Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev, 19, 1409-22.
  21. Wang S, Cao Q, Wang X, et al (2013). PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis. PLoS One, 8, 56797.
  22. Yasar Yildiz S, Kuru P, Toksoy Oner E, et al (2014). Functional stability of plasminogen activator inhibitor-1. Scientific World J, 2014, 858293.